Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 207

1.

Isogambogenic acid inhibits tumour angiogenesis by suppressing Rho GTPases and vascular endothelial growth factor receptor 2 signalling pathway.

Fan Y, Peng A, He S, Shao X, Nie C, Chen L.

J Chemother. 2013 Oct;25(5):298-308. doi: 10.1179/1973947813Y.0000000079.

PMID:
24070138
2.

Antiangiogenic mechanisms of PJ-8, a novel inhibitor of vascular endothelial growth factor receptor signaling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Carcinogenesis. 2012 May;33(5):1022-30. doi: 10.1093/carcin/bgs127. Epub 2012 Mar 20.

3.

PPemd26, an anthraquinone derivative, suppresses angiogenesis via inhibiting VEGFR2 signalling.

Huang SW, Lien JC, Kuo SC, Huang TF.

Br J Pharmacol. 2014 Dec;171(24):5728-42. doi: 10.1111/bph.12872.

4.

Morelloflavone, a biflavonoid, inhibits tumor angiogenesis by targeting rho GTPases and extracellular signal-regulated kinase signaling pathways.

Pang X, Yi T, Yi Z, Cho SG, Qu W, Pinkaew D, Fujise K, Liu M.

Cancer Res. 2009 Jan 15;69(2):518-25. doi: 10.1158/0008-5472.CAN-08-2531.

6.

Barbigerone, an isoflavone, inhibits tumor angiogenesis and human non-small-cell lung cancer xenografts growth through VEGFR2 signaling pathways.

Li X, Wang X, Ye H, Peng A, Chen L.

Cancer Chemother Pharmacol. 2012 Sep;70(3):425-37. doi: 10.1007/s00280-012-1923-x. Epub 2012 Jul 20.

PMID:
22814678
7.

Plumbagin inhibits tumour angiogenesis and tumour growth through the Ras signalling pathway following activation of the VEGF receptor-2.

Lai L, Liu J, Zhai D, Lin Q, He L, Dong Y, Zhang J, Lu B, Chen Y, Yi Z, Liu M.

Br J Pharmacol. 2012 Feb;165(4b):1084-96. doi: 10.1111/j.1476-5381.2011.01532.x.

8.

SKLB610: a novel potential inhibitor of vascular endothelial growth factor receptor tyrosine kinases inhibits angiogenesis and tumor growth in vivo.

Cao ZX, Zheng RL, Lin HJ, Luo SD, Zhou Y, Xu YZ, Zeng XX, Wang Z, Zhou LN, Mao YQ, Yang L, Wei YQ, Yu LT, Yang SY, Zhao YL.

Cell Physiol Biochem. 2011;27(5):565-74. doi: 10.1159/000329978. Epub 2011 Jun 15.

PMID:
21691074
9.

Anacardic acid (6-pentadecylsalicylic acid) inhibits tumor angiogenesis by targeting Src/FAK/Rho GTPases signaling pathway.

Wu Y, He L, Zhang L, Chen J, Yi Z, Zhang J, Liu M, Pang X.

J Pharmacol Exp Ther. 2011 Nov;339(2):403-11. doi: 10.1124/jpet.111.181891. Epub 2011 Aug 9.

11.

1'-Acetoxychavicol acetate suppresses angiogenesis-mediated human prostate tumor growth by targeting VEGF-mediated Src-FAK-Rho GTPase-signaling pathway.

Pang X, Zhang L, Lai L, Chen J, Wu Y, Yi Z, Zhang J, Qu W, Aggarwal BB, Liu M.

Carcinogenesis. 2011 Jun;32(6):904-12. doi: 10.1093/carcin/bgr052. Epub 2011 Mar 22.

12.

Acetyl-11-keto-beta-boswellic acid inhibits prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Pang X, Yi Z, Zhang X, Sung B, Qu W, Lian X, Aggarwal BB, Liu M.

Cancer Res. 2009 Jul 15;69(14):5893-900. doi: 10.1158/0008-5472.CAN-09-0755. Epub 2009 Jun 30.

13.

CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Ruggeri B, Singh J, Gingrich D, Angeles T, Albom M, Yang S, Chang H, Robinson C, Hunter K, Dobrzanski P, Jones-Bolin S, Pritchard S, Aimone L, Klein-Szanto A, Herbert JM, Bono F, Schaeffer P, Casellas P, Bourie B, Pili R, Isaacs J, Ator M, Hudkins R, Vaught J, Mallamo J, Dionne C.

Cancer Res. 2003 Sep 15;63(18):5978-91. Erratum in: Cancer Res. 2003 Nov 1;63(21):7543.

14.

Hispidulin, a small flavonoid molecule, suppresses the angiogenesis and growth of human pancreatic cancer by targeting vascular endothelial growth factor receptor 2-mediated PI3K/Akt/mTOR signaling pathway.

He L, Wu Y, Lin L, Wang J, Wu Y, Chen Y, Yi Z, Liu M, Pang X.

Cancer Sci. 2011 Jan;102(1):219-25. doi: 10.1111/j.1349-7006.2010.01778.x. Epub 2010 Nov 19.

15.

Luteolin inhibits human prostate tumor growth by suppressing vascular endothelial growth factor receptor 2-mediated angiogenesis.

Pratheeshkumar P, Son YO, Budhraja A, Wang X, Ding S, Wang L, Hitron A, Lee JC, Kim D, Divya SP, Chen G, Zhang Z, Luo J, Shi X.

PLoS One. 2012;7(12):e52279. doi: 10.1371/journal.pone.0052279. Epub 2012 Dec 31.

16.

Glyceollins, a novel class of soy phytoalexins, inhibit angiogenesis by blocking the VEGF and bFGF signaling pathways.

Lee SH, Lee J, Jung MH, Lee YM.

Mol Nutr Food Res. 2013 Feb;57(2):225-34. doi: 10.1002/mnfr.201200489. Epub 2012 Dec 10. Erratum in: Mol Nutr Food Res. 2013 Mar;57(3):556.

PMID:
23229497
17.

Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling.

Yi T, Yi Z, Cho SG, Luo J, Pandey MK, Aggarwal BB, Liu M.

Cancer Res. 2008 Mar 15;68(6):1843-50. doi: 10.1158/0008-5472.CAN-07-5944. Erratum in: Cancer Res. 2008 May 15;68(10):4012.

18.

YL529, a novel, orally available multikinase inhibitor, potently inhibits angiogenesis and tumour growth in preclinical models.

Xu Y, Lin H, Meng N, Lu W, Li G, Han Y, Dai X, Xia Y, Song X, Yang S, Wei Y, Yu L, Zhao Y.

Br J Pharmacol. 2013 Aug;169(8):1766-80. doi: 10.1111/bph.12216.

19.

YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models.

Xia Y, Song X, Li D, Ye T, Xu Y, Lin H, Meng N, Li G, Deng S, Zhang S, Liu L, Zhu Y, Zeng J, Lei Q, Pan Y, Wei Y, Zhao Y, Yu L.

Sci Rep. 2014 Aug 12;4:6031. doi: 10.1038/srep06031.

20.

Pristimerin, a triterpenoid, inhibits tumor angiogenesis by targeting VEGFR2 activation.

Mu X, Shi W, Sun L, Li H, Jiang Z, Zhang L.

Molecules. 2012 Jun 5;17(6):6854-68. doi: 10.3390/molecules17066854.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk